Patients with head and neck cancer who attended a survivorship clinic before completing RT were more likely to complete treatment on schedule and had better 3-year DFS than those who did not attend.

Adding irinotecan to adjuvant oxaliplatin-based chemotherapy does not improve 3-year disease-free survival in patients with ...

In the head-to-head TRANSCEND-T2D-2 trial, participants with type 2 diabetes (T2D) lost more than twice as much weight with retatrutide as with Ozempic (semaglutide) and had a greater reduction in A1c ...

Cancer survivors who adhered to the Dietary Approaches to Stop Hypertension (DASH) diet and other healthy eating patterns showed as much as a one-third lower risk of developing cardiovascular disease ...

Nearly 3 in 4 former National Football League (NFL) players who died between 2008 and 2023 likely had chronic traumatic encephalopathy (CTE), a new study suggested. The population-based ...

Patients with rheumatoid arthritis (RA) incidence in 2010-2019 achieved remission within the first year at higher rates than those diagnosed in 1990-1999. Median time to remission shortened from 6.4 ...

Short-acting bronchodilators remain the rescue inhalers for asthma and chronic obstructive pulmonary disease (COPD), yet the Global Initiative for Asthma (GINA) 2026 report states that asthma should ...

A patient started on a once-daily inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) inhaler for COPD and a patient started on that same class of inhaler ...

In COPD, two single-inhaler triple therapies have trial-based mortality findings that neither current US label includes as an efficacy claim. Trelegy Ellipta ...

In patients who presented to the emergency department (ED) with a possible myocardial infarction (MI), a point-of-care high-sensitivity cardiac troponin I (hs-cTnI) test was associated with shorter ...

For most patients starting maintenance therapy for COPD in 2026, a long-acting beta-agonist (LABA) prescribed alone is no longer the default first prescription. GOLD 2026 sorts patients not yet on ...

WASHINGTON — Children whose pediatricians recommended initiating the human papillomavirus (HPV) vaccination series at ages 9-10 had over twice the odds of starting and completing the series by age 13 ...